Development

Articles

The GMP facility is designed to maximize bioprocessing efficiency of newborn stem cells and manufacturing at scale.

Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility

GlaxoSmithKline and Alector have partnered to co-develop two mAbs for a range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease.

GSK and Alector Collaborate on Neurodegenerative Disease mAb Candidates

Feliza Mirasol is the science editor for 

The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.

Complex Biomolecules Require Analytical Evolution

The future pipeline of complex novel biotherapeutics will require new approaches to analytical assessment.

Meeting Future Analytical Requirements for Novel Biotherapeutics

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer.

Corbus Pharmaceuticals Expands Pipeline with Two New mAbs

AbbVie has exercised its right to acquire TeneoOne, along with its lead immunotherapeutic asset for the potential treatment of multiple myeloma.

AbbVie to Acquire TeneoOne and Lead Asset for Multiple Myeloma Treatment

FDA has granted breakthrough therapy designation to donanemab, Eli Lilly and Co.’s investigational antibody treatment for Alzheimer’s disease.

Lilly's Investigational Alzheimer's Therapeutic Gets Breakthrough Therapy Designation

The companies have entered into an agreement to develop processes for a novel immunotherapy protein.

SelectImmune and Lonza to Develop Immunotherapeutic Drug Candidate

GlaxoSmithKline and iTeos Therapeutics enter into a development and commercialization collaboration worth up to $2.08 billion for a new therapeutic anti-cancer mAb candidate.

Biologics APIs